[Pharmacokinetic Assessment]~Measurements~- Tegoprazan and desmethyl tegoprazan (M1) in blood and urine~Endpoints~Primary endpoints: AUClast and Cmax of tegoprazan and M1~Secondary endpoints: CL/F, t1/2, AUCinf, and fu of tegoprazan; CLrenal and Ae of tegoprazan and M1~[Safety Assessment]~Adverse events (AEs)~Clinical laboratory tests~Vital sign~Physical examination~Electrocardiogram (ECG)
The main purpose of this study is to compare the pharmacokinetic and safety of tegoprazan following single oral dose in subjects with hepatic impairment versus healthy control.